Fate Therapeutics (FATE) FCF Margin (2012 - 2026)
Fate Therapeutics (FATE) reported FCF Margin of 2373.9% for Q1 2026, down 25825.0% on a YoY basis from N/an in Q1 2025, and down 75.17% quarter-over-quarter from 1355.22% in Q4 2025.
Fate Therapeutics (FATE) FCF Margin (2012 - 2026) Analysis & Trends
Fate Therapeutics has reported FCF Margin for 14 years, with the latest figure at 2373.9% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 25825.0% year-over-year to 2373.9%; the trailing twelve-month figure through Mar 2026 stood at 1622.18% (down 69144.0% YoY), and the FY2025 full-year result was 1596.21%, down 69375.0% from the prior year.
- FCF Margin for Q1 2026 stood at 2373.9%, down from 1355.22% in the prior quarter.
- The five-year high for FCF Margin was 54.37% in Q1 2023, with the low at 3289.6% in Q2 2023.
- Historically, FCF Margin has averaged 1279.95% across 5 years, with a median of 1389.09% in 2025.
- Annual changes were most pronounced in 2023 — FCF Margin slumped 291225 bps — and 2024, when it soared 281125 bps.
- Fate Therapeutics' FCF Margin stood at 167.86% in 2022, then plunged by 990 bps to 1829.65% in 2023, then advanced by 18 bps to 1501.24% in 2024, then rose by 10 bps to 1355.22% in 2025, then tumbled by 75 bps to 2373.9% in 2026.
- The last three FCF Margin figures came in at 2373.9% (Q1 2026), 1355.22% (Q4 2025), and 1526.54% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - | -2,373.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,373.90% |
| Dec 31, 2025 | -1,355.22% |
| Sep 30, 2025 | -1,526.54% |
| Jun 30, 2025 | -1,389.09% |
| Mar 31, 2025 | -2,115.65% |
| Dec 31, 2024 | -1,501.24% |
| Sep 30, 2024 | -954.23% |
| Jun 30, 2024 | -478.35% |
| Mar 31, 2024 | -1,733.19% |
| Dec 31, 2023 | -1,829.65% |
| Sep 30, 2023 | -1,997.84% |
| Jun 30, 2023 | -3,289.60% |
| Mar 31, 2023 | -54.37% |
| Dec 31, 2022 | -167.86% |
| Sep 30, 2022 | -245.79% |
| Jun 30, 2022 | -377.35% |
| Mar 31, 2022 | -369.23% |
| Dec 31, 2021 | -416.20% |
| Sep 30, 2021 | -136.36% |
| Jun 30, 2021 | -340.93% |